Delayed gastric emptying, potential aspiration risks, and medication interactions — learn the hospitalist’s approach to ...

Findings from an international database seem encouraging but could be due to confounders or older GLP-1 receptor agonists.

Elevated levels of the gut hormone GLP-1 and its receptor may worsen brain inflammation and trigger severe symptoms in patients with neuromyelitis optica spectrum disorder (NMOSD), suggesting GLP-1 ...

Serena Williams is noticeably slimmer now than she was when she retired from the WTA Tour in 2022. Last month she revealed how that happened.

Initially marketed as diabetes treatments, GLP-1 drugs are now surging in popularity as weight loss solutions. With more ...

Novo Nordisk reported results from its phase 3 clinical trial for its experimental obesity drug cagrilintide which showed significant weight loss among participants. The research, presented at the ...

A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for ...

Analysis led by Mass General Brigham researchers shows tirzepatide offers greater value than semaglutide for most patients• For eligible and willing ...

The rollout of antiretroviral therapy for HIV showed how global solidarity and smart policy can overcome barriers to new treatments, say Jirair Ratevosian and Jeffrey L Sturchio The arrival of ...

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live ...

Eli Lilly and Co. (NYSE:LLY) is one of the best ESG stocks to buy now according to hedge funds. On September 9, Bank of America’s Tim Anderson reiterated a Buy rating on Eli Lilly & Co. (NYSE:LLY) and ...

Over the last four years, weight-loss drugs that dampen down appetite and promote satiety have revolutionised obesity ...